BACKGROUND: Health-related quality of life (HRQOL) of paediatric patients with osteosarcoma has not been documented longitudinally during treatment. Aims of this prospective study were to assess treatment effects on patients' HRQOL at diagnosis, during therapy and after completion of therapy, to assess sex- and age-related differences in HRQOL ratings and to assess differences between patients' and parents' reports. PATIENTS AND METHODS: Sixty-six patients (median age, 13.4 years) with newly diagnosed, localised disease completed three HRQOL instruments, and their parents completed two of the same instruments at diagnosis, before surgery (Week 12), at Week 23 and a median of 20 weeks after treatment completion. RESULTS: Significant improvements in most domains and worsening of nausea were reported by patients and parents from diagnosis to Weeks 12 and 23. Symptom distress decreased from diagnosis to Weeks 12 and 23 in 81% and 64% of patients, respectively. There were no sex- and few age-related differences in scores. Scores from patients and parents achieved good agreement. CONCLUSIONS: The HRQOL of patients improves during aggressive treatment for non-metastatic osteosarcoma, except in the domain of nausea. Clinicians can use these findings to prepare their patients for the distressing symptoms that they will likely experience at certain time points and to provide reassurance that these will significantly improve.
BACKGROUND: Health-related quality of life (HRQOL) of paediatric patients with osteosarcoma has not been documented longitudinally during treatment. Aims of this prospective study were to assess treatment effects on patients' HRQOL at diagnosis, during therapy and after completion of therapy, to assess sex- and age-related differences in HRQOL ratings and to assess differences between patients' and parents' reports. PATIENTS AND METHODS: Sixty-six patients (median age, 13.4 years) with newly diagnosed, localised disease completed three HRQOL instruments, and their parents completed two of the same instruments at diagnosis, before surgery (Week 12), at Week 23 and a median of 20 weeks after treatment completion. RESULTS: Significant improvements in most domains and worsening of nausea were reported by patients and parents from diagnosis to Weeks 12 and 23. Symptom distress decreased from diagnosis to Weeks 12 and 23 in 81% and 64% of patients, respectively. There were no sex- and few age-related differences in scores. Scores from patients and parents achieved good agreement. CONCLUSIONS: The HRQOL of patients improves during aggressive treatment for non-metastatic osteosarcoma, except in the domain of nausea. Clinicians can use these findings to prepare their patients for the distressing symptoms that they will likely experience at certain time points and to provide reassurance that these will significantly improve.
Authors: Victoria G Marchese; Susan Ogle; Richard B Womer; John Dormans; Jill P Ginsberg Journal: Pediatr Blood Cancer Date: 2004-01 Impact factor: 3.167
Authors: P S Hinds; A Quargnenti; A J Bush; C Pratt; D Fairclough; G Rissmiller; D Betcher; G S Gilchrist Journal: Eur J Oncol Nurs Date: 2000-03 Impact factor: 2.398
Authors: M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick Journal: N Engl J Med Date: 1986-06-19 Impact factor: 91.245
Authors: Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Pamela S Hinds; Catherine A Billups; Xueyuan Cao; Jami S Gattuso; Elizabeth Burghen; Nancy West; Jeffrey E Rubnitz; Najat C Daw Journal: Eur J Oncol Nurs Date: 2008-10-15 Impact factor: 2.398
Authors: D B Greenberg; A Goorin; M C Gebhardt; L Gupta; N Stier; D Harmon; H Mankin Journal: Oncology (Williston Park) Date: 1994-11 Impact factor: 2.990
Authors: Priya Patel; Sara R Lavoratore; Jacqueline Flank; Meaghan Kemp; Ashlee Vennettilli; Helen Vol; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; Paul C Nathan; L Lee Dupuis Journal: Support Care Cancer Date: 2019-06-08 Impact factor: 3.603
Authors: Samantha J Anthony; Enid Selkirk; Lillian Sung; Robert J Klaassen; David Dix; Katrin Scheinemann; Anne F Klassen Journal: Qual Life Res Date: 2013-08-02 Impact factor: 4.147
Authors: Helen Vol; Jacqueline Flank; Sara R Lavoratore; Paul C Nathan; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; L Lee Dupuis Journal: Support Care Cancer Date: 2015-09-03 Impact factor: 3.603
Authors: Johanna C Menard; Pamela S Hinds; Shana S Jacobs; Katie Cranston; Jichuan Wang; Darren A DeWalt; Heather E Gross Journal: Cancer Nurs Date: 2014 Jan-Feb Impact factor: 2.592